Company NexImmune, Inc.

Equities

NEXI

US65344D2080

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:30:00 09/05/2024 BST			5-day change	1st Jan Change
3.46 ^USD	+2.37%		+10.90%	+55.86%

04-17	North American Morning Briefing : Stock Futures -2-	DJ
04-16	NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the bodyâs own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.

Number of employees: 6

Managers	Title	Age	Since
Kristi Jones CEO	Chief Executive Officer	60	31/05/17
Mathias Oelke FOU	Founder	56	06/06/11
Tonya Catterton CMP	Compliance Officer	-	-
Chad Rubin IRC	Investor Relations Contact	-	20/04/21
Karen Haslbeck HRO	Human Resources Officer	-	31/08/19
Matthew Schiller PRN	Corporate Officer/Principal	-	13/07/21

Members of the board	Title	Age	Since
Sol Barer CHM	Chairman	76	15/12/19
Zheng Bin Yao BRD	Director/Board Member	58	31/12/16
Alan Roemer BRD	Director/Board Member	54	31/01/17
Grant Verstandig BRD	Director/Board Member	34	18/01/21
Tim Bertram BRD	Director/Board Member	68	31/12/16
Paul D'Angio BRD	Director/Board Member	65	31/12/16
Kristi Jones CEO	Chief Executive Officer	60	31/05/17
Leena Gandhi BRD	Director/Board Member	53	30/04/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,371,051	1,070,168 ( 78.05 %)	0	78.05 %

Name	Equities	%	Valuation
Sol Barer 7.497 %	88,712	7.497 %	497 674 $
Joshua Barer 6.370 %	75,383	6.370 %	422 899 $
Grant Verstandig 3.737 %	44,219	3.737 %	248 069 $
Slate Path Capital LP 3.127 %	36,999	3.127 %	207 564 $
Adage Capital Partners GP LLC 2.709 %	32,054	2.709 %	179 823 $
EPIQ Capital Group LLC 1.320 %	15,624	1.320 %	87 651 $
PNC Financial Services Group, Inc. (13F Subfiler) 1.068 %	12,640	1.068 %	70 910 $
Raymond James & Associates, Inc. 0.9130 %	10,804	0.9130 %	60 610 $
Comerica Bank (Dallas, Texas) 0.2752 %	3,256	0.2752 %	18 266 $
Tim Bertram 0.2643 %	3,127	0.2643 %	17 542 $

NexImmune, Inc.

9119 Gaither Road

20877, Gaithersburg

+301 825 9810

http://www.neximmune.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NEXIMMUNE, INC.	+55.86%	4.63M
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-12.77%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-6.50%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.53B

Bio Therapeutic Drugs